Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tumour microenvironment characterisation to stratify patients for hyperthermic intraperitoneal chemotherapy in high-grade serous ovarian cancer (OVHIPEC-1).

Autor: Aronson SL; Center for Gynecologic Oncology Amsterdam, Department of Gynecologic Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Walker C; Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, Bern, Switzerland.; Graduate School for Cellular and Biomedical Sciences, University of Bern, Bern, Switzerland., Thijssen B; Division of Molecular Carcinogenesis, Oncode Institute, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands., van de Vijver KK; Center for Gynecologic Oncology Amsterdam, Department of Gynecologic Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Pathology & Cancer Research Institute Ghent (CRIG), Ghent University Hospital, Ghent, Belgium., Horlings HM; Department of Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Sanders J; Department of Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Alkemade M; Core Facility Molecular Pathology and Biobanking, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Koole SN; Center for Gynecologic Oncology Amsterdam, Department of Gynecologic Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Lopez-Yurda M; Department of Biometrics, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Lok CAR; Center for Gynecologic Oncology Amsterdam, Department of Gynecologic Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Rottenberg S; Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, Bern, Switzerland.; Bern Center for Precision Medicine, University of Bern, Bern, Switzerland., van Rheenen J; Department of Molecular Pathology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Sonke GS; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., van Driel WJ; Center for Gynecologic Oncology Amsterdam, Department of Gynecologic Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. w.v.driel@nki.nl., Kester LA; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands., Hahn K; Department of Molecular Pathology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.

Publikováno v: British journal of cancer [Br J Cancer] 2024 Aug; Vol. 131 (3), pp. 565-576. Date of Electronic Publication: 2024 Jun 12.

Is routine admission to a critical care setting following hyperthermic intraperitoneal chemotherapy for ovarian cancer necessary?

Autor: van Stein RM; Dept. of Gynecologic Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands., Aronson SL; Dept. of Gynecologic Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands; Dept. of Medical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands., Sikorska K; Dept. of Biometrics Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands., Hendriks FJ; Dept. of Gynecology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, the Netherlands., Hovinga EP; Dept. of Gynecologic Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands., Houwink API; Dept. of Anesthesiology and Intensive Care, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands., Schutte PFE; Dept. of Anesthesiology and Intensive Care, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands., Schooneveldt MS; Dept. of Anesthesiology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, the Netherlands., De Kroon CD; Dept. of Gynecology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, the Netherlands., Sonke GS; Dept. of Medical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands., van Driel WJ; Dept. of Gynecologic Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands. Electronic address: OVHIPEC@nki.nl.

Publikováno v: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology [Eur J Surg Oncol] 2023 Dec; Vol. 49 (12), pp. 107084. Date of Electronic Publication: 2023 Oct 01.

Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer (OVHIPEC-1): final survival analysis of a randomised, controlled, phase 3 trial.

Autor: Aronson SL; Department of Gynecologic Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands., Lopez-Yurda M; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, Netherlands., Koole SN; Department of Gynecologic Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands., Schagen van Leeuwen JH; Department of Obstetrics and Gynecology, Sint Antonius Hospital, Nieuwegein, Netherlands., Schreuder HWR; Department of Gynecologic Oncology, UMC Utrecht Cancer Center, Utrecht, Netherlands., Hermans RHM; Department of Gynecology and Obstetrics, Catharina Hospital, Eindhoven, Netherlands., de Hingh IHJT; Department of Surgery, Catharina Hospital, Eindhoven, Netherlands; Department of Epidemiology, GROW-School for Oncology Reproduction, Maastricht University, Maastricht, Netherlands., van Gent MDJM; Department of Obstetrics and Gynecology, Amsterdam University Medical Center, Amsterdam, Netherlands; Center for Gynecologic Oncology Amsterdam, Amsterdam, Netherlands., Arts HJG; Department of Gynecologic Oncology, University Medical Center Groningen, Groningen, Netherlands., van Ham MAPC; Department of Gynecologic Oncology, Radboud University Medical Centre, Nijmegen, Netherlands., van Dam PA; Department of Gynecologic Oncology, University Hospital Antwerp, Antwerp, Belgium., Vuylsteke P; Department of Medical Oncology, UCL Louvain, CHU Namur Sainte-Elisabeth, Namur, Belgium; Department of Internal Medicine, University of Botswana, Gaborone, Botswana., Aalbers AGJ; Department of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands., Verwaal VJ; Department of Surgery, Skåne University Hospital, Malmö, Sweden., Van de Vijver KK; Department of Pathology, Ghent University Hospital, Ghent, Belgium., Aaronson NK; Division of Psychosocial Research and Epidemiology, Netherlands Cancer Institute, Amsterdam, Netherlands., Sonke GS; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands., van Driel WJ; Department of Gynecologic Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands; Center for Gynecologic Oncology Amsterdam, Amsterdam, Netherlands. Electronic address: w.v.driel@nki.nl.

Publikováno v: The Lancet. Oncology [Lancet Oncol] 2023 Oct; Vol. 24 (10), pp. 1109-1118. Date of Electronic Publication: 2023 Sep 11.

Future of HIPEC for ovarian cancer.

Autor: Aronson SL; Department of Gynaecological Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.; Department of Medical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands., van Stein RM; Department of Gynaecological Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands., Sonke GS; Department of Medical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands., van Driel WJ; Department of Gynaecological Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.

Publikováno v: BJOG : an international journal of obstetrics and gynaecology [BJOG] 2023 Jan; Vol. 130 (2), pp. 135-140. Date of Electronic Publication: 2022 Sep 25.